CN1535972A - 一种新的化合物及其制备方法和以该化合物为活性成分的药物制剂及其作用、用途 - Google Patents
一种新的化合物及其制备方法和以该化合物为活性成分的药物制剂及其作用、用途 Download PDFInfo
- Publication number
- CN1535972A CN1535972A CNA031093981A CN03109398A CN1535972A CN 1535972 A CN1535972 A CN 1535972A CN A031093981 A CNA031093981 A CN A031093981A CN 03109398 A CN03109398 A CN 03109398A CN 1535972 A CN1535972 A CN 1535972A
- Authority
- CN
- China
- Prior art keywords
- preparation
- compound
- water
- solvent
- gets
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 150000001875 compounds Chemical class 0.000 title claims abstract description 33
- 238000002360 preparation method Methods 0.000 title claims abstract description 26
- 239000003814 drug Substances 0.000 title claims abstract description 25
- 101100152731 Arabidopsis thaliana TH2 gene Proteins 0.000 claims description 40
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 16
- 239000000203 mixture Substances 0.000 claims description 14
- 239000002904 solvent Substances 0.000 claims description 14
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 claims description 12
- 229940079593 drug Drugs 0.000 claims description 12
- 230000006837 decompression Effects 0.000 claims description 11
- 238000001035 drying Methods 0.000 claims description 10
- 239000000825 pharmaceutical preparation Substances 0.000 claims description 9
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 claims description 8
- PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 claims description 8
- PJGUSJUWDDRXLN-UHFFFAOYSA-N chloroform;n-ethylethanamine;methanol Chemical compound OC.ClC(Cl)Cl.CCNCC PJGUSJUWDDRXLN-UHFFFAOYSA-N 0.000 claims description 8
- 239000000706 filtrate Substances 0.000 claims description 8
- 230000000259 anti-tumor effect Effects 0.000 claims description 7
- 229940117709 gamboge Drugs 0.000 claims description 7
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 claims description 6
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 claims description 6
- 239000003795 chemical substances by application Substances 0.000 claims description 6
- 238000009472 formulation Methods 0.000 claims description 6
- 239000007788 liquid Substances 0.000 claims description 6
- 238000000034 method Methods 0.000 claims description 6
- 239000000741 silica gel Substances 0.000 claims description 6
- 229910002027 silica gel Inorganic materials 0.000 claims description 6
- 239000002775 capsule Substances 0.000 claims description 5
- 229940124321 AIDS medicine Drugs 0.000 claims description 4
- 238000002425 crystallisation Methods 0.000 claims description 4
- 230000008025 crystallization Effects 0.000 claims description 4
- 238000003810 ethyl acetate extraction Methods 0.000 claims description 4
- 238000002347 injection Methods 0.000 claims description 4
- 239000007924 injection Substances 0.000 claims description 4
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims description 4
- 239000012046 mixed solvent Substances 0.000 claims description 4
- 239000000178 monomer Substances 0.000 claims description 4
- 239000006187 pill Substances 0.000 claims description 4
- -1 polyoxyethylene Polymers 0.000 claims description 4
- 238000010898 silica gel chromatography Methods 0.000 claims description 4
- 125000000391 vinyl group Chemical group [H]C([*])=C([H])[H] 0.000 claims description 4
- 229920002554 vinyl polymer Polymers 0.000 claims description 4
- 239000008187 granular material Substances 0.000 claims description 3
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 3
- 229920003171 Poly (ethylene oxide) Polymers 0.000 claims description 2
- 239000000443 aerosol Substances 0.000 claims description 2
- 238000006386 neutralization reaction Methods 0.000 claims description 2
- 238000007920 subcutaneous administration Methods 0.000 claims description 2
- 239000000829 suppository Substances 0.000 claims description 2
- 239000003826 tablet Substances 0.000 claims description 2
- 241000598812 Garcinia tinctoria Species 0.000 claims 4
- 239000004475 Arginine Substances 0.000 claims 2
- ODKSFYDXXFIFQN-BYPYZUCNSA-P L-argininium(2+) Chemical compound NC(=[NH2+])NCCC[C@H]([NH3+])C(O)=O ODKSFYDXXFIFQN-BYPYZUCNSA-P 0.000 claims 2
- XUYPXLNMDZIRQH-LURJTMIESA-N N-acetyl-L-methionine Chemical compound CSCC[C@@H](C(O)=O)NC(C)=O XUYPXLNMDZIRQH-LURJTMIESA-N 0.000 claims 2
- 235000001014 amino acid Nutrition 0.000 claims 2
- 150000001413 amino acids Chemical class 0.000 claims 2
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 claims 2
- 229930182817 methionine Natural products 0.000 claims 2
- 230000001476 alcoholic effect Effects 0.000 claims 1
- 239000003513 alkali Substances 0.000 claims 1
- 229940041181 antineoplastic drug Drugs 0.000 claims 1
- 230000015572 biosynthetic process Effects 0.000 claims 1
- 229910052500 inorganic mineral Inorganic materials 0.000 claims 1
- 239000011707 mineral Substances 0.000 claims 1
- 235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 claims 1
- 229920000053 polysorbate 80 Polymers 0.000 claims 1
- 150000003839 salts Chemical class 0.000 claims 1
- 206010028980 Neoplasm Diseases 0.000 abstract description 9
- 201000011510 cancer Diseases 0.000 abstract description 5
- 208000030507 AIDS Diseases 0.000 abstract description 4
- 125000004974 2-butenyl group Chemical group C(C=CC)* 0.000 abstract 1
- 229920002472 Starch Polymers 0.000 description 14
- 239000008107 starch Substances 0.000 description 14
- 235000019698 starch Nutrition 0.000 description 14
- 239000002994 raw material Substances 0.000 description 10
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 9
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 8
- 230000000694 effects Effects 0.000 description 7
- 239000004480 active ingredient Substances 0.000 description 5
- 239000000463 material Substances 0.000 description 5
- 235000020985 whole grains Nutrition 0.000 description 5
- 102000004190 Enzymes Human genes 0.000 description 4
- 108090000790 Enzymes Proteins 0.000 description 4
- 241000598860 Garcinia hanburyi Species 0.000 description 4
- ODKSFYDXXFIFQN-BYPYZUCNSA-N L-arginine Chemical compound OC(=O)[C@@H](N)CCCN=C(N)N ODKSFYDXXFIFQN-BYPYZUCNSA-N 0.000 description 4
- 229930064664 L-arginine Natural products 0.000 description 4
- 235000014852 L-arginine Nutrition 0.000 description 4
- 229920000168 Microcrystalline cellulose Polymers 0.000 description 4
- 238000003556 assay Methods 0.000 description 4
- 201000010099 disease Diseases 0.000 description 4
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 4
- 235000019359 magnesium stearate Nutrition 0.000 description 4
- 235000019813 microcrystalline cellulose Nutrition 0.000 description 4
- 239000008108 microcrystalline cellulose Substances 0.000 description 4
- 229940016286 microcrystalline cellulose Drugs 0.000 description 4
- 239000002002 slurry Substances 0.000 description 4
- 239000000126 substance Substances 0.000 description 4
- 238000012360 testing method Methods 0.000 description 4
- 239000008215 water for injection Substances 0.000 description 4
- 241000713772 Human immunodeficiency virus 1 Species 0.000 description 3
- 208000005718 Stomach Neoplasms Diseases 0.000 description 3
- 230000001093 anti-cancer Effects 0.000 description 3
- 238000005469 granulation Methods 0.000 description 3
- 230000003179 granulation Effects 0.000 description 3
- 208000032839 leukemia Diseases 0.000 description 3
- 201000007270 liver cancer Diseases 0.000 description 3
- 208000014018 liver neoplasm Diseases 0.000 description 3
- 230000000452 restraining effect Effects 0.000 description 3
- 239000007787 solid Substances 0.000 description 3
- 239000000243 solution Substances 0.000 description 3
- 238000003756 stirring Methods 0.000 description 3
- 201000000498 stomach carcinoma Diseases 0.000 description 3
- 230000002103 transcriptional effect Effects 0.000 description 3
- 206010058467 Lung neoplasm malignant Diseases 0.000 description 2
- 238000007605 air drying Methods 0.000 description 2
- 235000013339 cereals Nutrition 0.000 description 2
- 230000008034 disappearance Effects 0.000 description 2
- 238000007908 dry granulation Methods 0.000 description 2
- 230000005496 eutectics Effects 0.000 description 2
- 230000002401 inhibitory effect Effects 0.000 description 2
- 201000005202 lung cancer Diseases 0.000 description 2
- 208000020816 lung neoplasm Diseases 0.000 description 2
- 206010025482 malaise Diseases 0.000 description 2
- 229910021424 microcrystalline silicon Inorganic materials 0.000 description 2
- 238000002156 mixing Methods 0.000 description 2
- 239000002245 particle Substances 0.000 description 2
- 238000005453 pelletization Methods 0.000 description 2
- 239000008194 pharmaceutical composition Substances 0.000 description 2
- 239000000047 product Substances 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 239000000523 sample Substances 0.000 description 2
- 239000011122 softwood Substances 0.000 description 2
- 208000012991 uterine carcinoma Diseases 0.000 description 2
- 238000001644 13C nuclear magnetic resonance spectroscopy Methods 0.000 description 1
- 238000005160 1H NMR spectroscopy Methods 0.000 description 1
- JGSARLDLIJGVTE-UHFFFAOYSA-N 3,3-dimethyl-7-oxo-6-[(2-phenylacetyl)amino]-4-thia-1-azabicyclo[3.2.0]heptane-2-carboxylic acid Chemical compound O=C1N2C(C(O)=O)C(C)(C)SC2C1NC(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-UHFFFAOYSA-N 0.000 description 1
- WVDDGKGOMKODPV-UHFFFAOYSA-N Benzyl alcohol Chemical compound OCC1=CC=CC=C1 WVDDGKGOMKODPV-UHFFFAOYSA-N 0.000 description 1
- LISIMNLOQIEWAZ-UHFFFAOYSA-N C(=O)(O)[Na].[P] Chemical compound C(=O)(O)[Na].[P] LISIMNLOQIEWAZ-UHFFFAOYSA-N 0.000 description 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
- 241000725303 Human immunodeficiency virus Species 0.000 description 1
- 229930195725 Mannitol Natural products 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 230000000996 additive effect Effects 0.000 description 1
- 230000000840 anti-viral effect Effects 0.000 description 1
- 235000019445 benzyl alcohol Nutrition 0.000 description 1
- 229960004217 benzyl alcohol Drugs 0.000 description 1
- IAQRGUVFOMOMEM-UHFFFAOYSA-N butene Natural products CC=CC IAQRGUVFOMOMEM-UHFFFAOYSA-N 0.000 description 1
- 208000019065 cervical carcinoma Diseases 0.000 description 1
- 229940126678 chinese medicines Drugs 0.000 description 1
- LDHQCZJRKDOVOX-NSCUHMNNSA-N crotonic acid Chemical compound C\C=C\C(O)=O LDHQCZJRKDOVOX-NSCUHMNNSA-N 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 238000004992 fast atom bombardment mass spectroscopy Methods 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 239000012467 final product Substances 0.000 description 1
- 238000004108 freeze drying Methods 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 239000000594 mannitol Substances 0.000 description 1
- 235000010355 mannitol Nutrition 0.000 description 1
- 239000012982 microporous membrane Substances 0.000 description 1
- 230000001613 neoplastic effect Effects 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- 230000003000 nontoxic effect Effects 0.000 description 1
- 239000003921 oil Substances 0.000 description 1
- 238000011275 oncology therapy Methods 0.000 description 1
- 239000005022 packaging material Substances 0.000 description 1
- 238000012856 packing Methods 0.000 description 1
- 229940124531 pharmaceutical excipient Drugs 0.000 description 1
- 239000002831 pharmacologic agent Substances 0.000 description 1
- 239000002574 poison Substances 0.000 description 1
- 231100000614 poison Toxicity 0.000 description 1
- 239000013641 positive control Substances 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 239000011347 resin Substances 0.000 description 1
- 229920005989 resin Polymers 0.000 description 1
- 230000001954 sterilising effect Effects 0.000 description 1
- 238000004659 sterilization and disinfection Methods 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 238000012546 transfer Methods 0.000 description 1
- BKOOMYPCSUNDGP-UHFFFAOYSA-N trimethyl-ethylene Natural products CC=C(C)C BKOOMYPCSUNDGP-UHFFFAOYSA-N 0.000 description 1
- 238000013022 venting Methods 0.000 description 1
Landscapes
- Medicinal Preparation (AREA)
- Medicines Containing Plant Substances (AREA)
Abstract
Description
Claims (10)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN 03109398 CN1289505C (zh) | 2003-04-08 | 2003-04-08 | 新化合物藤黄新酸的化学结构及以其为活性成份的药物制剂和用途 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN 03109398 CN1289505C (zh) | 2003-04-08 | 2003-04-08 | 新化合物藤黄新酸的化学结构及以其为活性成份的药物制剂和用途 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN1535972A true CN1535972A (zh) | 2004-10-13 |
CN1289505C CN1289505C (zh) | 2006-12-13 |
Family
ID=34319317
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN 03109398 Expired - Fee Related CN1289505C (zh) | 2003-04-08 | 2003-04-08 | 新化合物藤黄新酸的化学结构及以其为活性成份的药物制剂和用途 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN1289505C (zh) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1927861B (zh) * | 2006-07-06 | 2011-01-26 | 中国药科大学 | 一种藤黄酸衍生物及其制备方法和在制药中的应用 |
Families Citing this family (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN103421021B (zh) * | 2010-06-11 | 2016-08-10 | 台湾森本生物科技开发股份有限公司 | 分离自藤黄树脂的化合物暨其衍生物,以及包含有此等化合物与衍生物的药学组成物 |
TWI432191B (zh) | 2010-06-11 | 2014-04-01 | Taiwan Sunpan Biotechnology Dev Co Ltd | 分離自藤黃樹脂的化合物以及包含有此等化合物的藥學組成物 |
CN102276621B (zh) * | 2010-06-11 | 2015-01-07 | 台湾森本生物科技开发股份有限公司 | 分离自藤黄树脂的化合物暨其衍生物,以及包含有此等化合物与衍生物的药学组成物 |
-
2003
- 2003-04-08 CN CN 03109398 patent/CN1289505C/zh not_active Expired - Fee Related
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1927861B (zh) * | 2006-07-06 | 2011-01-26 | 中国药科大学 | 一种藤黄酸衍生物及其制备方法和在制药中的应用 |
Also Published As
Publication number | Publication date |
---|---|
CN1289505C (zh) | 2006-12-13 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN1709460A (zh) | 山绿茶滴丸及其制备方法 | |
CN1245398C (zh) | 黄芩素的提取工艺、药用组合物及制剂制备工艺 | |
CN1903183A (zh) | 替比夫定分散片及其制备方法 | |
CN1289505C (zh) | 新化合物藤黄新酸的化学结构及以其为活性成份的药物制剂和用途 | |
CN1225464C (zh) | 汉黄芩素的提取工艺、药用组合物及制剂制备工艺 | |
CN1307979C (zh) | 紫珠止血滴丸及其制备方法 | |
CN1543943A (zh) | 口服水飞蓟素缓释制剂及其制备方法 | |
CN1179726C (zh) | 柚皮苷在制备支持性治疗非典型性肺炎药物中的应用 | |
CN1686362A (zh) | 毛冬青滴丸及其制备方法 | |
CN1309125A (zh) | 具抗癌活性的藤黄酸类化合物的复合物及其制备方法 | |
CN1903869A (zh) | 替比夫定的衍生物盐及其制备方法和药物应用 | |
CN1438225A (zh) | 一种姜黄色素金属离子配合物及其制备方法和应用 | |
CN1623993A (zh) | 新型的斑蝥胺和去甲斑蝥胺衍生物及其在医药中的应用 | |
CN1301107C (zh) | 以穿心莲内酯磺化物制备而成的滴丸及其制备方法 | |
CN1634478A (zh) | 川贝枇杷滴丸及其制备方法 | |
CN1210019C (zh) | Ii型胶原水溶性分散组合物及其制备方法和应用 | |
CN1718184A (zh) | 具有抗肿瘤活性的新藤黄酸复合物、制备方法及其制剂和用途 | |
CN1327386A (zh) | 抗hiv感染症剂及hiv感染症的治疗方法 | |
CN1686436A (zh) | 一种用于止咳祛痰的口服滴丸及其制备方法 | |
CN1679675A (zh) | 一种具有清热解毒作用的穿黄消炎滴丸及其制备方法 | |
CN1294902C (zh) | 一种采用满山红制备而成的消咳喘滴丸 | |
CN1634145A (zh) | 一种治疗脑炎、肝昏迷的醒脑静滴丸及其制备方法 | |
CN1307978C (zh) | 四季消炎滴丸及其制备方法 | |
CN1301094C (zh) | 一种治疗口腔疾病的喉痛消炎滴丸及其制备方法 | |
CN1850071A (zh) | 联苯双酯固体分散体、其制备方法及含其的缓释制剂 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
ASS | Succession or assignment of patent right |
Owner name: WANG XIANRONG; APPLICANT Free format text: FORMER OWNER: TIANKE DRUG RESEARCH INSTITUTE, ANHUI PROVINCE; APPLICANT Effective date: 20060303 |
|
C41 | Transfer of patent application or patent right or utility model | ||
TA01 | Transfer of patent application right |
Effective date of registration: 20060303 Address after: 230061, room 257, 202 village, amber villa, Hefei, Anhui Applicant after: Wang Xianrong Co-applicant after: Huang Zhengming Address before: The research of medical science Hefei 230061 Anhui province Yonghong Road No. 15 Applicant before: Tianke Inst. of Medicine, Anhui Prov. Co-applicant before: Beijing Academy of Military Medicine, PLA |
|
C14 | Grant of patent or utility model | ||
GR01 | Patent grant | ||
C17 | Cessation of patent right | ||
CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20061213 Termination date: 20120408 |